InMed Pharmaceuticals Inc. Logo

InMed Pharmaceuticals Inc.

Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.

INM | US

Overview

Corporate Details

ISIN(s):
CA4576375022
LEI:
Country:
United States of America
Address:
1445-885 WEST GEORGIA ST., VANCOUVER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing a proprietary pipeline of small molecule drug candidates targeting the CB1 and CB2 receptors. The company's main therapeutic programs address significant unmet medical needs, including preclinical candidates for Alzheimer’s disease (INM-901) and dry age-related macular degeneration (INM-089), as well as a completed Phase 2 clinical trial for epidermolysis bullosa. Additionally, through its subsidiary BayMedica, InMed manufactures and supplies high-purity, bioidentical rare cannabinoids (including CBC, d9-THCV, CBDV, and CBTC) as raw ingredients for the B2B health and wellness product market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all InMed Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for InMed Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for InMed Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea 354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea 138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
Nkarta, Inc. Logo
Developing off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America NKTX
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America NLSP
NovaBay Pharmaceuticals, Inc. Logo
Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.
United States of America NBY
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland NOVN

Talk to a Data Expert

Have a question? We'll get back to you promptly.